Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Operating Leases (2019 - 2025)

Historic Operating Leases for Corcept Therapeutics (CORT) over the last 9 years, with Q3 2025 value amounting to $6.4 million.

  • Corcept Therapeutics' Operating Leases fell 637.61% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 637.61%. This contributed to the annual value of $6.1 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Corcept Therapeutics' Operating Leases stood at $6.4 million, which was down 637.61% from $6.6 million recorded in Q2 2025.
  • Corcept Therapeutics' Operating Leases' 5-year high stood at $6.8 million during Q1 2025, with a 5-year trough of $76000.0 in Q1 2024.
  • Its 4-year average for Operating Leases is $3.4 million, with a median of $2.5 million in 2022.
  • As far as peak fluctuations go, Corcept Therapeutics' Operating Leases tumbled by 8688.16% in 2023, and later skyrocketed by 889342.11% in 2025.
  • Over the past 4 years, Corcept Therapeutics' Operating Leases (Quarter) stood at $1.1 million in 2022, then plummeted by 80.31% to $225000.0 in 2023, then skyrocketed by 2614.22% to $6.1 million in 2024, then increased by 4.11% to $6.4 million in 2025.
  • Its Operating Leases stands at $6.4 million for Q3 2025, versus $6.6 million for Q2 2025 and $6.8 million for Q1 2025.